The ESTRO Global Impact of Radiotherapy in Oncology (GIRO) partnership was launched at ESTRO 36 in May 2017 to pursue a data-driven approach to improving radiotherapy access worldwide. The GIRO partnership aims to unite leaders in radiation oncology to tackle current problems, problem- solve for solutions, and ultimately improve cancer outcomes and save lives.

With that vision in mind, GIRO is initiating a first international patterns of care study in radiation oncology. It aims to evaluate the use of hypofractionated external beam radiotherapy in the treatment of breast cancer, prostate cancer, cervical cancer and bone metastases.

You are invited to participate in this survey because of your experience as a practicing radiation oncologist. We hope this information will help us to understand how evidence is shared within our community and what the drivers and/or barriers to adopt specific treatment strategies are and to support the development of new models for radiotherapy delivery.

Please complete the survey by accessing the link

The survey must be answered in a single session and should take approximately 10 minutes to complete. Your participation in this survey is completely voluntary and all responses will be kept confidential and anonymized.

Thank you for your commitment and participation,

Please visit us at